Table 1 Patient demographics and baseline characteristics
From: Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
Overall N = 166 | Chronic migraine N = 71 | Episodic migraine N = 95 | p—value | |
|---|---|---|---|---|
Age, years, mean (SD) | 37.8 (8.99) | 38.8 (9.51) | 37.1 (8.57) | 0.2502 |
Age categories, years, n (%) | ||||
≥ 18 to < 35 | 65 (39.2) | 24 (33.8) | 41 (43.2) | 0.0498 |
≥ 35 to < 50 | 89 (53.6) | 38 (53.5) | 51 (53.7) | |
≥ 50 | 12 (7.2) | 9 (12.7) | 3 (3.2) | |
Sex, female, n (%) | 124 (74.7) | 49 (69.0) | 75 (78.9) | |
Ethnicity, n (%) | ||||
Local | 123 (74.1) | 53 (74.6) | 70 (73.7) | 0.8885 |
Non local | 43 (25.9) | 18 (25.4) | 25 (26.3) | |
Arab | 27 (16.3) | 12 (16.9) | 15 (15.8) | |
Asian | 4 (2.4) | 1 (1.4) | 3 (3.2) | |
Western | 4 (2.4) | 2 (2.8) | 2 (2.1) | |
European | 7 (4.2) | 3 (4.2) | 4 (4.2) | |
Other | 1 (0.6) | 0 | 1 (1.1) | |
BMI, kg/m2, mean (SD) | 28.2 (4.76) | 28.4 (4.97) | 28.1 (4.66) | 0.8322 |
BMI category, kg/m2, n (%) | ||||
≥ 18.5 to < 25 | 20 (26.0) | 8 (25.8) | 12 (26.1) | 0.9985 |
≥ 25 to < 30 | 32 (41.6) | 13 (41.9) | 19 (41.3) | |
> 30 | 25 (32.5) | 10 (32.3) | 15 (32.6) | |
Family history of migraine, n (%) | ||||
Yes | 51 (30.7) | 21 (29.6) | 30 (31.6) | 0.8952 |
No | 76 (45.8) | 34 (47.9) | 42 (44.2) | |
Unknown | 39 (23.5) | 16 (22.5) | 23 (24.2) | |
Duration of migraine, years, mean (SD) | 5.0 (9.75) | 6.0 (7.82) | 4.4 (10.92) | 0.0223 |
Age at migraine onset, years, mean (SD) | 29.0 (7.93) | 29.4 (8.35) | 28.7 (7.63) | 0.5352 |
MHD over the past 1 month, days, mean (SD) | 15.6 (8.54) | 22.9 (6.35) | 9.0 (3.05) | < 0.0001 |
MHD at baseline, days, mean (SD) | 15.7 (8.45) | 22.9 (6.57) | 9.2 (2.93) | NA |
MSMD at baseline, days, mean (SD) | 12.8 (10.00) | 18.6 (8.55) | 7.4 (8.11) | |
Number of PPTFs, n (%) | ||||
0 | 72 (43.4) | 31 (43.7) | 41 (43.2) | 0.4886 |
1 | 28 (16.9) | 14 (19.7) | 14 (14.7) | |
2 | 34 (20.5) | 10 (14.1) | 24 (25.3) | |
3 | 5 (3.0) | 2 (2.8) | 3 (3.2) | |
4 | 17 (10.2) | 8 (11.3) | 9 (9.5) | |
≥ 5 | 10 (6.0) | 6 (8.5) | 4 (4.2) | |
Number of classes of preventive therapy used previously, n (%) | ||||
1 | 34 (20.5) | 9 (12.7) | 25 (26.3) | |
2 | 10 (6.0) | 2 (2.8) | 8 (8.4) | |
3 | 5 (3.0) | 4 (5.6) | 1 (1.1) | |
> 3 | 4 (2.4) | 2 (2.8) | 2 (2.1) | |